This is an open-label, single-arm clinical trial. Trial participants will include men and
women, aged 18-60 years who have had a first demyelinating event within the previous 180 days
and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which
are at least 3 mm in diameter, and at least one of which is ovoid or periventricular or
infra-tentorial. Treatment with minocycline until the endpoint is reached or to a maximum of
24 months or until the last-enrolled participant reaches their 12 month visit.